PL2265288T3 - Sposoby leczenia bólu zapalnego - Google Patents

Sposoby leczenia bólu zapalnego

Info

Publication number: PL2265288T3
Authority: PL; Poland
Prior art keywords: methods; inflammatory pain; treating inflammatory; treating; pain
Prior art date: 2008-03-04

Application number

PL09716779T

Other languages

English (en)

Inventor

Laura Corradini

Ian Machin

Kristian Todd Poulsen

David Louis Shelton

Joerg Zeller

Original Assignee

Labrys Biologics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-04

Filing date

2009-03-03

Publication date

2017-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40823474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2265288(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-03 Application filed by Labrys Biologics Inc filed Critical Labrys Biologics Inc

2017-01-31 Publication of PL2265288T3 publication Critical patent/PL2265288T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL09716779T 2008-03-04 2009-03-03 Sposoby leczenia bólu zapalnego PL2265288T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3356808P	2008-03-04	2008-03-04

Publications (1)

Publication Number	Publication Date
PL2265288T3 true PL2265288T3 (pl)	2017-01-31

Family

ID=40823474

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09716779T PL2265288T3 (pl)	2008-03-04	2009-03-03	Sposoby leczenia bólu zapalnego

Country Status (19)

Country	Link
US (6)	US8298536B2 (pl)
EP (2)	EP3115062A1 (pl)
JP (3)	JP5745861B2 (pl)
KR (1)	KR101304085B1 (pl)
CN (2)	CN101959529A (pl)
AU (1)	AU2009220897B2 (pl)
BR (1)	BRPI0908276B8 (pl)
CA (1)	CA2716799C (pl)
DK (1)	DK2265288T3 (pl)
ES (1)	ES2584907T3 (pl)
HK (1)	HK1232130A1 (pl)
IL (1)	IL207439B (pl)
MX (1)	MX2010009724A (pl)
NZ (1)	NZ587297A (pl)
PL (1)	PL2265288T3 (pl)
PT (1)	PT2265288T (pl)
RU (1)	RU2467765C2 (pl)
WO (1)	WO2009109908A1 (pl)
ZA (1)	ZA201006070B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3534353B2 (ja)	1994-03-08	2004-06-07	ミサワホーム株式会社	建物ユニットの耐火構造
SI3045182T1 (en)	2005-11-14	2018-08-31	Teva Pharmaceuticals International Gmbh	An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
MX2010009724A (es) *	2008-03-04	2010-09-28	Pfizer Ltd	Procedimientos de tratamiento del dolor inflamatorio-.
KR101304150B1 (ko)	2008-03-04	2013-09-05	라브리스 바이올로직스 인코포레이티드	만성 통증의 치료 방법
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
BR112012004464B8 (pt)	2009-08-28	2021-05-25	Labrys Biologics Inc	uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
JO3330B1 (ar) *	2010-06-10	2019-03-13	Lilly Co Eli	الأجسام المضادة cgrp
PT3495392T (pt)	2011-05-20	2021-09-22	H Lundbeck As	Composições anti-cgrp e a sua utilização
CN108014334B (zh)	2011-05-20	2021-11-30	H.伦德贝克公司	抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
EA033109B1 (ru)	2011-05-20	2019-08-30	Олдербайо Холдингз Ллк	Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
WO2013168004A2 (en) *	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of fibromyalgia pain
RU2535095C2 (ru) *	2013-01-09	2014-12-10	Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства"	Композиция для трансдермальной доставки в организм лекарственных веществ и лекарственная форма на ее основе
KR101439032B1 (ko) *	2013-06-13	2014-09-05	동아에스티 주식회사	피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) *	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es)	2014-03-21	2025-03-10	Teva Pharmaceuticals Int Gmbh	Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
UY36302A (es)	2014-09-15	2016-04-29	Amgen Inc	Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
JP6508670B2 (ja) *	2014-12-26	2019-05-08	国立大学法人広島大学	軟骨変性抑制剤
TWI728953B (zh)	2015-04-24	2021-06-01	美商安美基公司	治療或預防偏頭痛之方法
ES2914684T3 (es)	2015-08-19	2022-06-15	Univ Iowa Res Found	Terapia preventiva para la artrosis postraumática
WO2017132062A1 (en)	2016-01-28	2017-08-03	Eli Lilly And Company	Cgrp antibodies and uses thereof
SMT202600087T1 (it)	2016-09-23	2026-03-09	Teva Pharmaceuticals Int Gmbh	Trattamento dell’emicrania refrattaria
US11771662B2 (en)	2017-09-05	2023-10-03	Kansas State University Research Foundation	Analgesic formulation for control of pain in dogs
US11274158B2 (en) *	2018-01-30	2022-03-15	Flagship Pioneering Innovations V, Inc.	Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
SG11202009629YA (en)	2018-04-02	2020-10-29	Amgen Inc	Erenumab compositions and uses thereof
US10899826B1 (en)	2018-09-13	2021-01-26	Teva Pharmaceuticals International Gmbh	Pharmaceutical compositions for an anti-CGRP antagonist antibody
CR20210373A (es)	2019-01-08	2021-08-19	H Lundbeck As	Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
GEAP202515803A (en)	2019-05-02	2025-06-10	H Lundbeck As	Treatment of headache using anti-cgrp antibodies
CN114127110B (zh) *	2019-05-30	2022-07-01	山东博安生物技术股份有限公司	抗cgrp抗体及其应用
WO2020263989A1 (en)	2019-06-24	2020-12-30	University Of Iowa Research Foundation	Jnk inhibitors as anticancer agents
WO2021015342A1 (ko) *	2019-07-24	2021-01-28	의료법인 성광의료재단	Trpv4 길항제를 포함하는 척수 손상 예방 또는 치료용 조성물
US11904006B2 (en)	2019-12-11	2024-02-20	University Of Iowa Research Foundation	Poly(diaminosulfide) particle-based vaccine
KR20210124867A (ko)	2020-04-06	2021-10-15	하. 룬드벡 아크티에셀스카브	항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
CN112142838B (zh) *	2020-07-23	2021-11-16	杭州傲锐生物医药科技有限公司	一种卡利普多人工抗原及其多抗和应用
CN115181099B (zh) *	2021-04-02	2024-01-16	南京舒鹏生物科技有限公司	一种醌类化合物及其药学应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
DE59711622D1 (de)	1996-09-10	2004-06-17	Boehringer Ingelheim Pharma	Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6063768A (en)	1997-09-04	2000-05-16	First; Eric R.	Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
IL160271A0 (en) *	2001-09-19	2004-07-25	Altana Pharma Ag	Pharmaceutical compositions containing pde4-inhibitors and nsaid
US7026312B2 (en)	2002-03-14	2006-04-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7879991B2 (en)	2002-05-06	2011-02-01	Noxxon Pharma Ag	CGRP binding nucleic acids
DE10250082A1 (de)	2002-10-25	2004-05-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en)	2002-10-25	2009-09-29	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
EP1722792A1 (de)	2004-03-03	2006-11-22	Boehringer Ingelheim International GmbH	Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE102004015723A1 (de) *	2004-03-29	2005-10-20	Boehringer Ingelheim Pharma	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004027912A1 (de)	2004-06-09	2005-12-29	Grünenthal GmbH	Substituierte Cyclopenten-Verbindungen
EP1770091A1 (de) *	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
SI3045182T1 (en) *	2005-11-14	2018-08-31	Teva Pharmaceuticals International Gmbh	An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
CA2629406A1 (en) *	2005-11-18	2007-05-31	Merck & Co., Inc.	Spirohydantoin aryl cgrp receptor antagonists
WO2007076336A1 (en)	2005-12-22	2007-07-05	Eli Lilly And Company	Treatment of migraine with anti-cgrp antibodies
US7834000B2 (en)	2006-06-13	2010-11-16	Vertex Pharmaceuticals Incorporated	CGRP receptor antagonists
JP5511379B2 (ja) *	2006-07-21	2014-06-04	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｇｒｐレセプターアンタゴニスト
MX2010009724A (es) *	2008-03-04	2010-09-28	Pfizer Ltd	Procedimientos de tratamiento del dolor inflamatorio-.

2009
- 2009-03-03 MX MX2010009724A patent/MX2010009724A/es active IP Right Grant
- 2009-03-03 CN CN2009801076217A patent/CN101959529A/zh active Pending
- 2009-03-03 WO PCT/IB2009/050849 patent/WO2009109908A1/en not_active Ceased
- 2009-03-03 RU RU2010136974/15A patent/RU2467765C2/ru active
- 2009-03-03 CA CA2716799A patent/CA2716799C/en active Active
- 2009-03-03 NZ NZ587297A patent/NZ587297A/xx unknown
- 2009-03-03 PL PL09716779T patent/PL2265288T3/pl unknown
- 2009-03-03 US US12/920,634 patent/US8298536B2/en active Active
- 2009-03-03 EP EP16167233.2A patent/EP3115062A1/en not_active Withdrawn
- 2009-03-03 EP EP09716779.5A patent/EP2265288B1/en not_active Revoked
- 2009-03-03 CN CN201610214202.5A patent/CN106110321A/zh active Pending
- 2009-03-03 PT PT97167795T patent/PT2265288T/pt unknown
- 2009-03-03 BR BRPI0908276A patent/BRPI0908276B8/pt active IP Right Grant
- 2009-03-03 JP JP2010549235A patent/JP5745861B2/ja active Active
- 2009-03-03 DK DK09716779.5T patent/DK2265288T3/en active
- 2009-03-03 KR KR1020107019880A patent/KR101304085B1/ko not_active Expired - Fee Related
- 2009-03-03 ES ES09716779.5T patent/ES2584907T3/es active Active
- 2009-03-03 AU AU2009220897A patent/AU2009220897B2/en active Active
2010
- 2010-08-05 IL IL207439A patent/IL207439B/en active IP Right Grant
- 2010-08-25 ZA ZA2010/06070A patent/ZA201006070B/en unknown
2013
- 2013-05-10 US US13/892,130 patent/US20130295088A1/en not_active Abandoned
2015
- 2015-05-07 JP JP2015094963A patent/JP2015145420A/ja active Pending
2016
- 2016-04-21 US US15/135,363 patent/US20170073398A1/en not_active Abandoned
2017
- 2017-03-09 JP JP2017044704A patent/JP6363242B2/ja active Active
- 2017-06-09 HK HK17105710.9A patent/HK1232130A1/en unknown
- 2017-11-21 US US15/819,868 patent/US20180305443A1/en not_active Abandoned
2019
- 2019-06-04 US US16/430,522 patent/US20200148752A1/en not_active Abandoned
2021
- 2021-02-24 US US17/184,220 patent/US20220017608A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20220017608A1 (en)	2022-01-20
US20110054150A1 (en)	2011-03-03
BRPI0908276A2 (pt)	2015-08-18
US20200148752A1 (en)	2020-05-14
CA2716799A1 (en)	2009-09-11
CN101959529A (zh)	2011-01-26
JP5745861B2 (ja)	2015-07-08
HK1232130A1 (en)	2018-01-05
JP6363242B2 (ja)	2018-07-25
JP2011513386A (ja)	2011-04-28
CA2716799C (en)	2018-05-22
JP2017105835A (ja)	2017-06-15
RU2467765C2 (ru)	2012-11-27
CN106110321A (zh)	2016-11-16
WO2009109908A8 (en)	2010-08-19
JP2015145420A (ja)	2015-08-13
BRPI0908276B1 (pt)	2020-11-10
IL207439B (en)	2019-01-31
NZ587297A (en)	2012-10-26
ES2584907T3 (es)	2016-09-30
EP2265288B1 (en)	2016-05-11
WO2009109908A1 (en)	2009-09-11
KR20100112195A (ko)	2010-10-18
AU2009220897A1 (en)	2009-09-11
US20130295088A1 (en)	2013-11-07
DK2265288T3 (en)	2016-06-06
EP2265288A1 (en)	2010-12-29
PT2265288T (pt)	2016-07-14
BRPI0908276B8 (pt)	2021-05-25
EP3115062A1 (en)	2017-01-11
MX2010009724A (es)	2010-09-28
KR101304085B1 (ko)	2013-09-05
US20170073398A1 (en)	2017-03-16
IL207439A0 (en)	2010-12-30
AU2009220897B2 (en)	2014-09-18
US20180305443A1 (en)	2018-10-25
ZA201006070B (en)	2011-06-29
RU2010136974A (ru)	2012-03-10
US8298536B2 (en)	2012-10-30

Publication	Publication Date	Title
IL207439A0 (en)	2010-12-30	Methods of treating inflammatory pain
IL207752A0 (en)	2010-12-30	Methods of treating inflammation
EP2331564A4 (en)	2013-02-20	PROCESS FOR TREATMENT OF IGNITION
IL208354A0 (en)	2010-12-30	Methods of treatment
ZA201006069B (en)	2011-05-25	Methods of treating chronic pain
IL217777A0 (en)	2012-03-29	Methods for treatment of pain
ZA201101823B (en)	2014-08-27	Treating inflammatory conditions
ZA201009030B (en)	2012-03-28	Methods of treating inflammatory colon disease
ZA201303605B (en)	2014-11-26	Compounds and methods for treating pain
IL211061A0 (en)	2011-04-28	Methods of treating thalassemia
ZA201207118B (en)	2016-08-31	Method of treatment of prophylaxis of inflammatory pain
PT2435825E (pt)	2015-11-02	Métodos para o tratamento de doenças
IL214664A0 (en)	2011-09-27	Methods of treating hair related conditions
EP2480579A4 (en)	2013-07-31	METHODS OF TREATING INFLAMMATION
DK2473482T3 (en)	2014-05-12	Methods of treating orthomyxoviral infections
VN25747A1 (en)	2011-04-25	Method of water treatment
IL205452A0 (en)	2010-12-30	Methods of treating scleroderma
EP2164494A4 (en)	2010-06-02	Methods of Treatment
ZA201108493B (en)	2013-01-30	Method of treating hair
GB0723100D0 (en)	2008-01-02	Treatment of HFnEF
EP2303284A4 (en)	2013-04-24	METHOD FOR TREATING BIPOLAR DISORDER
ZA201005206B (en)	2011-09-28	Method of treating hair
GB0819446D0 (en)	2008-12-03	Treatment of inflammatory disorders
EP2203432A4 (en)	2011-04-27	PROCESSING METHOD
ZA201006046B (en)	2013-01-30	Methods of treating inflammation